This article provides detailed analysis of South Korean port container weight limit issues, sharing practical experience for 20ft and 40ft containers to help foreign trade practitioners avoid risks.
This article deeply analyzes the composition of common port miscellaneous fees for LCL shipping to Busan Port in South Korea, the influencing factors of fee levels, and provides practical suggestions for cost reduction, helping foreign trade enterprises optimize logistics costs.
Deeply introduce the sea transportation process of PE diaphragms exported from Shanghai to Busan, South Korea, covering key links such as customs declaration, insurance and document preparation.
Details the process and precautions for exporting disinfection products, especially for the US, EU and South Korean markets. Includes the classification of regulatory agencies, product registration, compliance obligations and response strategies for temporary policies.
The supervision and certification process for imported new energy vehicles in Singapore covers multiple departments and detailed technical regulations. This article provides an in - depth introduction to Singapores main regulatory agencies, applicable technical regulations, certification processes, and import procedures.
This article provides an in - depth introduction to South Koreas regulatory agencies, technical regulations, conformity assessment procedures, and import procedures for the import of new energy vehicles, providing a comprehensive import guide for enterprises.
The market access process for medical devices in South Korea is relatively complex, involving multiple steps and the participation of multiple departments. This article will briefly introduce the certification and registration processes required for exporting medical devices to South Korea.
Exporting to South Korea
On June 26, 2023, the Ministry of Food and Drug Safety (MFDS) of South Korea submitted Notification G/TBT/N/KOR/1150 to the WTO, proposing revisions to the Regulations on Licensing and Review of Biological Products, etc. to enhance domestic biological product safety. The revisions include definitions for new terms such as live bacterial preparations, quality audit requirements for Quality by Design (QbD) systems, expansion of the Scientific Citation Index scope for pharmacological and clinical trial data, changes to stability test data submission requirements for manufacturing method modifications, mandatory submission procedures for Risk Management Plans (RMP) for self-injection products approved by MFDS, and establishment of evaluation standards for RNA and DNA vaccines. Given that China is the worlds second-largest biological product market, these revisions have significant implications for Chinese exporters, who must closely monitor and adapt to these changes.
? 2025. All Rights Reserved. Shanghai ICP No. 2023007705-2 
PSB Record: Shanghai No.31011502009912
